Trials / Completed
CompletedNCT00723905
Remicade Infusion Management Program
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,630 (actual)
- Sponsor
- Janssen Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Janssen Inc. plans to collect data on about 3000 to 5000 infliximab infusions per year, starting in the third quarter of 2005. It is expected that about 12 sites from the Remicade Infusion Network (R.I.N.) will participate. This registry will be a multicentre, prospective, observational program that will gather and analyze data on subjects being treated with infliximab.
Conditions
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2012-10-01
- Completion
- 2012-10-01
- First posted
- 2008-07-29
- Last updated
- 2013-01-15
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT00723905. Inclusion in this directory is not an endorsement.